Kiralis is a pre-revenue startup founded in mid-2018. The company’s vision is to enable the development of safer drugs and chemicals by providing access to pure enantiomers affordable and timely.

Kiralis offers several value propositions to customers in the Pharma, Agritech, Food, and Fragrance industries.

**Objective:** Help Kiralis understand the value of its chiral-induced spin selectivity (CISS) technology, assess the costs involved, and identify potential partners.

1. Understand customers in the drug development and manufacturing industries
2. Assess the costs, challenges and opportunities in chiral molecule separation
3. Find potential partners in venture funds, CRO, bioinformatics,
4. Present findings and recommendations

**Options for Profitability**
- Partner with Pharmaceutical
- Partner with CROs
- Partner with Bioinformatics firms

**Product Strategies**
- Focus on Separation Technology
- Focus on Separation and Synthesis Technology

**Misc. Findings**
- Seek out pharma venture funds
- Provide project-based work
- Provide a continuous manufacturing process